Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2011 | 04:10am CEST

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTELLAS PHARMA INC
08/25 ASTELLAS PHARMA : and World Transplant Games Federation Announce Launch of Fit f..
08/24 ASTELLAS PHARMA : Announces Personnel Changes
08/23 ASTELLAS PHARMA : Announces Personnel Changes (pdf 47KB)
08/22 ASTELLAS PHARMA : and World Transplant Games Federation Announce Launch of Fit f..
08/16 ASTELLAS PHARMA : Farma Brasil Ranked Among 20 Greatest Workplaces in Brazil
08/11 ASTELLAS PHARMA : Announces Transfer of U.S. Manufacturing Subsidiary to Avara
08/11 ASTELLAS PHARMA : Findings from Astellas Pharma, Inc. in Gamma-aminobutyric Acid..
08/09 PROTEOSTASIS THERAPEUTICS : Achieves Preclinical Milestone in Astellas Pharma Co..
08/05 ASTELLAS PHARMA : Transfers Manufacturing Subsidiary to Avara
08/05 ASTELLAS PHARMA : transfers US manufacturing subsidiary to Avara Norman Pharma
More news
Sector news : Pharmaceuticals - NEC
01:56pDJMYLAN : Feeling Heat on EpiPen Price, Will Offer Cheaper Generic
11:29aDJROCHE : Receives US FDA Emergency Use Authorization for Zika Test -- Update
11:10aDJROCHE : Receives US FDA Emergency Use Authorization for Zika Test
09:29aDJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08/27 Stada shareholder AOC pushes through board reshuffle
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/24 PFIZER-MEDIVATION DEAL : Good Or Bad For Shareholders?
08/23 Who's Next After Medivation?
08/22 Pfizer Pays Up
08/18 The 'Safest' Healthcare Top Dogs Of August?
08/16 Biotechnology Dogs Move Big Pharma Off Healthcare Top Slots In August
Advertisement
Financials ( JPY)
Sales 2017 1 335 385 M
EBIT 2017 280 000 M
Net income 2017 199 303 M
Finance 2017 299 195 M
Yield 2017 2,19%
P/E ratio 2017 16,90
P/E ratio 2018 15,64
EV / Sales 2017 2,34x
EV / Sales 2018 2,20x
Capitalization 3 424 579 M
More Financials
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 1 977  JPY
Spread / Average Target 24%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yoshihiko Hatanaka President, CEO & Representative Director
Masafumi Nogimori Chairman
Yasumasa Masuda Senior Executive Officer & Head-Finance
Mitsunori Matsuda Senior Executive Officer & GM-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC-7.45%33 619
JOHNSON & JOHNSON15.89%325 679
ROCHE HOLDING LTD.-12.84%214 671
PFIZER INC.7.87%211 206
NOVARTIS AG-10.83%210 234
ASTRAZENECA PLC7.33%173 797
More Results